Regulation of selective PPARγ modulators in the differentiation of osteoclasts

Journal of Cellular Biochemistry

Volumn 114, Issue 9, 2013, Pages 1969-1977

  Wu, Haochen ^a   Li, Long ^a   Ma, Yong ^b   Chen, Yongjun ^a   Zhao, Jingfa ^a   Lu, Yan ^a   Shen, Pingping ^a  

^a NANJING UNIVERSITY   (China)

^b NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

DIABETES; OSTEOCLAST; OSTEOPOROSIS; PPAR ; SPPAR Ms

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ROSIGLITAZONE; TELMISARTAN; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6;

ANIMAL CELL; ARTICLE; BONE MARROW CELL; CELL DIFFERENTIATION; CONTROLLED STUDY; ENZYME ACTIVITY; MONONUCLEAR CELL; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOCLASTOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

MUS;

EID: 84881380354     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.24534     Document Type: Article

References (25)

1. Benson SC, Pershadsingh HA, Ho CI, Chittiboyina A, Desai P, Pravenec M, Qi N, Wang J, Avery MA, Kurtz TW,. 2004. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPAR gamma-modulating activity. Hypertension 43: 993.
2. Boyle WJ, Simonet WS, Lacey DL,. 2003. Osteoclast differentiation and activation. Nature 423: 337.
3. Chaput E, Saladin R, Silvestre M, Edgar AD,. 2000. Fenofibrate and rosiglitazone lower serum triglycerides with opposing effects on body weight. Biochem Bioph Res Co 271: 445.
4. Derosa G, Ragonesi PD, Mugellini A, Ciccarelli L, Fogari R,. 2004. Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, type 2 diabetic patients: A randomized, double-blind, placebo-controlled 12-month study. Hypertens Res 27: 457.
5. Grigoriadis AE, Wang ZQ, Cecchini MG, Hofstetter W, Felix R, Fleisch HA, Wagner EF,. 1994. c-Fos: A key regulator of osteoclast-macrophage lineage determination and bone remodeling. Science 27: 443.
6. Hotokezaka H,., Sakai E, Kanaoka K, Saito K, Matsuo K, Kitaura H, Yoshida N, Nakayama K,. 2002. U0126 and PD98059, specific inhibitors of MEK, accelerate differentiation of RAW264.7 cells into osteoclast-like cells. J Biol Chem 277: 47366.
7. Kasukawa Y, Stabnov L, Miyakoshi N, Baylink DJ, Mohan S,. 2002. Insulin-likegrowth factor I effect on the number of osteoblast progenitors is impaired in ovariectomizedmice. J Bone Miner Res 17: 1579.
8. Kawano H, Sato T, Yamada T, Matsumoto T, Sekine K, Watanabe T, Nakamura T, Fukuda T, Yoshimura K, Yoshizawa T, Aihara K, Yamamoto Y, Nakamichi Y, Metzger D, Chambon P, Nakamura K, Kawaguchi H, Kato S,. 2003. Suppressive function of androgen receptor in bone resorption. Proc Natl Acad Sci 100: 9416.
9. King, EJ, Haboubi H, Evans D, Baker I, Bain SC, Stephens JW,. 2012. The management of diabetes in terminal illness related to cancer. Q J Med 105: 3.
10. Kiviranta R, Morko J, Uusitalo H, Aro HT, Vuorio E, Rantakokko J,. 2001. Accelerated turnover of metaphyseal trabecular bone in mice overexpressing cathepsin K. J Bone Miner Res 16: 1444.
11. Kobayashi N, Kadono Y, Naito A, Matsumoto K, Yamamoto T, Tanaka S, Inoue J,. 2001. Segregation of TRAF6-mediated signaling pathways clarifies its role in osteoclastogenesis. Embo J 20: 1271.
12. Lacey D, Timms E, Tan H, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian Y, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ,. 1998. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93: 165.
13. Ma L, Ji JL, Ji H, Yu X, Ding LJ, Liu K, Li YQ,. 2010. Telmisartan alleviates rosiglitazone-induced bone loss in ovariectomized spontaneous hypertensive rats. Bone 47: 5.
14. Matsuo K, Galson DL, Zhao C, Peng L, Laplace C, Wang K, Bachler MA, Amano H, Aburatani H, Ishikawa H, Wagner EF,. 2004. Nuclear factor of activated T-cells (NFAT) rescues osteoclastogenesis in precursors lacking c-Fos. J Biol Chem 279: 26475.
15. Maurin AC, Chavassieux PM, Meunier PJ,. 2005. Expression of PPARgamma and beta/delta in human primary osteoblastic cells: Influence of polyunsaturated fatty acids. Calcif Tissue Int 76: 385.
16. Neale SD, Smith R, Wass JA, Athanasou NA,. 2000. Osteoclast differentiation from circulating mononuclear precursors in Paget's disease is hypersensitive to 1,25-dihydroxyvitamin D(3) and RANKL. Bone 27: 409.
17. Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, Horton ES, Winter ML, Porte D, Semenkovich CF, Smith S, Young LH, Kahn R,. 2003. Thiazolidinedione use, fluid retention, and congestive heart failure: A consensus statement from the American Heart Association and American Diabetes Association. Circulation 108: 2941.
18. Nicholson AC, Hajjar DP,. 2004. CD36, oxidized LDL and PPAR gamma: Pathological interactions in macrophages and atherosclerosis. Vasc Pharmacol 41: 139.
19. Rocchi S, Picard F, Vamecq J, Gelman L, Potier N, Zeyer D, Dubuquoy L, Bac P, Champy MF, Plunket KD, Leesnitzer LM, Blanchard SG, Desreumaux P, Moras D, Renaud JP, Auwerx J,. 2001. A unique PPARγ ligand with potent insulin-sensitizing yet weak adipogenic activity. Mol Cell 8: 737.
20. Rzonca, SO, Gaddy LJ, Montague DC, Czernik BL,. 2004. Bone is a target for the antidiabetic compound rosiglitazone. Endocrinology 145: 401.
21. Takahashi N, Yamaha H, Yoshiki S, Roodman GD, Mundy GR, Jones SJ, Boyde A, Suda T,. 1988. Osteoclast-like cell formation and its regulation by osteotropic hormones in mouse bone marrow cultures. Endocrinology 122: 1373.
22. Tontonoz P, Spiegelman BM,. 2008. Fat and beyond: The diverse biology of PPARγ. Annu Rev Biochem 77: 289.
23. Wan YH, Chong LW, Evans RM,. 2007. PPAR-γ regulates osteoclastogenesis in mice. Nat Med 13: 1496.
24. Wei W, Wang XQ, Yang M, Smith LC, Dechow PC, Wan YH,. 2010. PGC1β mediates PPARγ activation of osteoclastogenesis and rosiglitazone-induced bone loss. Cell Metab 11: 503.
25. Willson TM, Cobb JE, Cowan DJ, Wiethe RW, Correa ID, Prakesh SR, Beck KD, Moore LB, Kliewer SA, Lehmann JM,. 1996. The structure-activity relationship between peroxisome proliferator-activated receptorγ agonism and the antihyperglycemic activity of thiazolidinediones. J Med Chem 39: 665.